Publications & Presentations

Check out the latest scientific presentations from Kailera Therapeutics.

Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA (HRS-7535) in Chinese Patients with Type 2 Diabetes Inadequately Controlled by Metformin and SGLT2 Inhibitor

M. Ren et al.
European Association for the Study of Diabetes (EASD)
September 2025

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Chinese Adults with Overweight or Obesity Without Diabetes

Q. Wen et al.
European Association for the Study of Diabetes (EASD)
September 2025

Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide-1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin

L. Guo et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide-1 Receptor Agonist (HRS-7535) in Chinese Adults with Obesity without Diabetes

W. Gu et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Participants with Type 2 Diabetes Mellitus (T2DM): a Randomized, Double-Blind, Placebo Controlled Phase 2 Trial

J. Zhao et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Chinese Adults with Obesity without Diabetes—Up to 52-Week Treatment

L. Zhao et al.
American Diabetes Association (ADA) 2025
June 2025

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants: A Phase 1 Study

W. Hu et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Chinese Adults with Overweight or Obesity Without Diabetes

J. Zhou et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Patients with Type 2 Diabetes Mellitus (T2DM): A Randomized, Double-blind, Placebo-controlled Phase 2 Trial

J. Zhao et al.
European Association for the Study of Diabetes (EASD) 2024
September 2024